A significant insight into their biology and variable clinical behavior began to emerge when isocitrate dehydrogenase 1 and 2 (IDH1/2) mutations were discovered in 10% of glioblastomas (GBMs) and subsequently in a large proportion of LGAs2. This evidence concerns the gene IDH1 and glioblastoma.